| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
|
Medicine details |
|
| Medicine name | interferon beta-1a (Avonex®) |
| Formulation | solution for injection |
| Reference number | 171 |
| Indication | Treatment of ambulatory patients with relapsing multiple sclerosis (MS) characterised by at least two recurrent attacks of neurologic dysfunctions in preceeding 3 year period. Treatment of patients who have experienced a single severe demyelinating event with an active inflammatory process |
| Company | Biogen Idec Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 23/01/2002 |
| NICE guidance | TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |